Lv2
150 积分 2024-02-17 加入
Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy
10小时前
待确认
Hepatectomy alters adjuvant anti-PD-1 action in a mouse model of HCC but does not compromise neoadjuvant efficacy
1个月前
已完结
Step-by-Step Approach to Intracorporeal Urinary Diversion, Ileal Conduit, and W-Neobladder: The Roswell Park Technique
3个月前
已完结
Re-Rechallenge 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
4个月前
已完结
Clinical Trial Protocol for LuCAB: A Phase I–II Trial Evaluating Cabazitaxel in Combination with [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer
4个月前
已完结
Short-term Prostate-specific Antigen Pseudoregression Following [177Lu]–Prostate-specific Membrane Antigen Therapy
4个月前
已完结
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
4个月前
已完结
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
4个月前
已完结
Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial
5个月前
已完结
177Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer
5个月前
已完结
皖公网安备34019202002308
